HSPPC-96
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Cancer
Conditions
Kidney Cancer, Renal Cell Carcinoma
Trial Timeline
May 1, 2005 → Mar 1, 2006
NCT ID
NCT00126178About HSPPC-96
HSPPC-96 is a phase 3 stage product being developed by Agenus for Kidney Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00126178. Target conditions include Kidney Cancer, Renal Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Cancer were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01147536 | Phase 2 | Terminated |
| NCT00293423 | Phase 1/2 | Completed |
| NCT00126178 | Phase 3 | Terminated |
| NCT00098085 | Phase 2 | Completed |
Competing Products
20 competing products in Kidney Cancer